tldrdailynews.com logo
Tag

Psychedelics

All articles tagged with #psychedelics

Psilocybin sparks memory recall in advanced Alzheimer’s case, study finds
health13 days ago

Psilocybin sparks memory recall in advanced Alzheimer’s case, study finds

A Japanese-American woman in her 80s with advanced Alzheimer’s showed notable functional gains—recalling personal memories, bladder control, dressing, and spontaneous social interaction—after a five-gram psilocybin session, with additional improvements after a subsequent three-gram dose a month later. Some benefits persisted weeks later, but researchers caution this is early-stage, not a cure, and stress the need for controlled clinical trials.

via CTV News|
#alzheimers-disease#case-study#health
High-dose psilocybin briefly revives function in advanced Alzheimer's: a case study
science15 days ago

High-dose psilocybin briefly revives function in advanced Alzheimer's: a case study

A published Frontiers in Neuroscience case report describes an 80-year-old woman with advanced Alzheimer's who temporarily regained urinary continence, walking ability, self-care, and conversational capacity after a single five-gram dose of psilocybin-containing mushrooms (with a follow-up three-gram session showing continued improved verbal expression). While the improvements spanned multiple domains and persisted for weeks, researchers caution that this is a single observational case without controls or standardized testing, and not evidence of a cure. The findings suggest dormant brain-network capacities may be temporarily re-engaged by psychedelic-induced neuroplasticity, highlighting the need for formal, controlled trials and safety assessments, particularly in vulnerable older adults; ongoing studies like UC Berkeley's PLASTICITY aim to explore aging brains and neuroplasticity with psychedelics.

via PsyPost|
#alzheimers-disease#case-report#neuroplasticity
Psychedelics Could Open the Mind's Eye for People with Aphantasia
science15 days ago

Psychedelics Could Open the Mind's Eye for People with Aphantasia

Neuroscience research shows about 3% of people have aphantasia, a mind's-eye blind spot. Case studies suggest psychedelics like ayahuasca and psilocybin may enable mental imagery in some individuals—sometimes long after the experience—by altering brain signaling and connectivity between visual, memory, and executive networks. While intriguing for understanding consciousness, a controlled, ethical trial is needed to confirm mechanisms, assess safety, and determine how such psychedelic-induced imagery might help or impact those with aphantasia.

via Yahoo|
#aphantasia#consciousness#mental-imagery
LSD-Based DT120 Delivers Promising Depression Relief in Phase III Trial
health19 days ago

LSD-Based DT120 Delivers Promising Depression Relief in Phase III Trial

Definium Therapeutics reports that a single 100‑microgram dose of its LSD‑based DT120 significantly reduced major depressive disorder symptoms versus placebo in a 149‑participant Phase III trial across 20 sites, with a week‑6 average 8.1‑point greater drop on a standard depression scale, about 35% of DT120 users achieving a 50%+ improvement (vs 7% placebo), and 12% in remission (vs 3%), with effects persisting through 12 weeks. The company plans FDA expedited review pending results from a second Phase III trial (Ascend) and continued development of DT120 for anxiety disorders, signaling potential for rapid, durable relief from a single treatment if approved.

via Gizmodo|
#depression#fda#health
Psychedelic single-dose therapy boosts cocaine abstinence in small trial
health1 month ago

Psychedelic single-dose therapy boosts cocaine abstinence in small trial

A randomized JAMA Network Open trial found that a single psilocybin dose, paired with psychotherapy, increased cocaine abstinence versus placebo among 36 participants, highlighting a potential new treatment since there are no FDA-approved cocaine-use meds. Experts say psilocybin may act as a catalyst for behavioral change via neuroplasticity, not as a maintenance drug. However, the small size, specific exclusions (no comorbid depression/anxiety), and recruitment nuances limit generalizability, and larger trials are needed. Notably, the study included a majority of Black participants, a first for psychedelic trials.

via The Guardian|
#clinical-trial#cocaine-addiction#health
One Psilocybin Dose May Rewire the Brain for Weeks
science1 month ago

One Psilocybin Dose May Rewire the Brain for Weeks

A UCSF and Imperial College London study found that a single 25 mg dose of psilocybin increases brain entropy during the experience and is followed by lasting changes in brain connectivity for about a month, alongside reported boosts in psychological insight and well-being. The results suggest the psychedelic experience itself may drive durable mental health benefits and could inform optimized psilocybin-based therapies.

via SciTechDaily|
#brain-entropy#nature-communications#neural-connectivity
Tiny psilocybin study links intense trips to brain wiring changes
science2 months ago

Tiny psilocybin study links intense trips to brain wiring changes

A small 28-participant study finds that after a 25 mg psilocybin dose, diffusion tensor imaging shows changes in water diffusion along neural fibers—especially in tracts linking the prefrontal cortex with other brain regions—with stronger trips associated with larger changes; about 70% of participants reported improved well-being 2–4 weeks later, suggesting psychedelic-induced brain plasticity, though results are exploratory and require replication in larger trials.

via NBC News|
#brain-plasticity#diffusion-tensor-imaging#neuroimaging
Psilocybin-assisted therapy shows potential to help people quit smoking
health2 months ago

Psilocybin-assisted therapy shows potential to help people quit smoking

A BBC Health report describes a randomized trial where a single high dose of psilocybin (about 30 mg, with 10 CBT sessions) plus talk therapy led to significantly higher smoking cessation than nicotine patches: 52% abstinent at six months in 82 participants vs 25% in the patch group. These findings, echoing earlier smaller studies, suggest psychedelics can trigger neuroplastic changes and a shift in priorities that support quitting, and are driving a larger NIH-funded, multi-site follow-up study to confirm efficacy and understand mechanisms. However, experts caution the sample was small and not highly diverse, so results may not generalize, and long-term safety and durability remain to be seen.

via BBC|
#clinical-trials#health#neuroplasticity
Trump Signs Order to Fast-Track Psychedelic Therapies for Veterans
politics2 months ago

Trump Signs Order to Fast-Track Psychedelic Therapies for Veterans

President Trump signed an executive order to accelerate research and access to psychedelic medicines—highlighting ibogaine—as potential treatments for serious mental illnesses and focusing on veterans with PTSD and suicide risk. The order directs cross‑agency collaboration (DOJ, HHS, VA, FDA), aims for faster regulatory review through science‑based pathways, and includes a $50 million federal funding commitment for ibogaine research and expanded access in licensed, hospital‑grade settings, all while maintaining rigorous safety standards.

via The White House (.gov)|
#executive-order#ibogaine#mental-health
Trump pushes fast-track reviews for psychedelic medicines
politics2 months ago

Trump pushes fast-track reviews for psychedelic medicines

President Trump issued an executive order directing the FDA (and DEA) to fast-track reviews for psychedelic drugs and to establish a pathway for access to investigational psychedelics under FDA review, including granting priority review vouchers for three serotonin 2A agonists. Companies like Compass Pathways welcomed the move as a step toward faster, regulated access to psychedelic medicines for mental illness while maintaining scientific rigor.

via Fierce Biotech|
#breakthrough-therapy-designation#compass-pathways#executive-order
Trump signs order to fast-track psychedelic research, including ibogaine
politics2 months ago

Trump signs order to fast-track psychedelic research, including ibogaine

President Trump signed an executive order to ease federal restrictions on psychedelic research, including ibogaine, with a $50 million funding commitment and a pathway for ibogaine to be studied and used under the FDA's Right To Try for seriously ill patients. The FDA will also add three psychedelics to the National Priority Voucher program to accelerate reviews, while maintaining oversight and not legalizing the drugs. The move aims to spur new mental-health treatments but underscores safety concerns and the need for more robust clinical trials.

via CBS News|
#fda#ibogaine#politics